Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a groundbreaking gene-editing and molecular detection tool that allows scientists to precisely identify, modify, and analyze specific DNA or RNA sequences. First discovered as a natural defense mechanism in bacteria and archaea, CRISPR protects these organisms from viral infections by storing fragments of viral DNA in their genomes. This "genetic memory" enables them to recognize and destroy the same viruses if they return.
In the lab, researchers have adapted this system for targeted genetic engineering.
The CRISPR toolkit consists of two key components:
When the guide RNA matches a target DNA or RNA sequence—such as a disease-related gene or a pathogen’s genome—the Cas enzyme binds to the site and either edits the sequence (e.g., correcting mutations) or triggers a detectable signal (e.g., fluorescence) to confirm the target’s presence.
Compared to older gene-editing tools, CRISPR offers faster, more precise, and cost-effective RNA-guided targeting. It can edit or detect virtually any DNA or RNA sequence, and enzymes like Cas12 and Cas13 enhance detection by cleaving nearby molecules, amplifying signals for genome editing and rapid disease diagnostics.
CRISPR-TB™ is a blood-based molecular assay designed to detect circulating Mycobacterium tuberculosis complex (MTBC) cell-free DNA (cfDNA) in plasma.
Powered by qPCR amplification and CRISPR-Cas12a detection, CRISPR-TB enables highly specific sequence targeting for tuberculosis detection, including cases where sputum-based testing may be difficult or limited.
CRISPR-TB is designed to support tuberculosis evaluation across a broader disease spectrum, including pulmonary TB, extrapulmonary TB, pediatric populations, and sputum-scarce patients.
Key features include:

This streamlined workflow supports timely detection and may help address diagnostic gaps in populations where traditional sample collection is challenging.
Clinical studies have shown CRISPR-TB performance across pulmonary and extrapulmonary TB, including adult and pediatric cohorts. CRISPR-TB has also shown strong correlation with clinical treatment response, supporting its potential value across TB detection and monitoring applications.
MTBC cell-free DNA is released during active replication and disease progression, enabling detection across pulmonary and extrapulmonary TB.

MTBC cfDNA has been detected in patientswith extrapulmonary manifestations, includinglymphatic, pleural, disseminated, and othernon-pulmonary sites.


Our proprietary CRISPR/Cas system, boosted by thermostable polymerase, identifies pathogens with unmatched precision.

Fluorescent markers light up upon target binding, delivering immediate, quantifiable insights.

Detect SNPs, pathogens, and cancer cells—all on a single platform.

Streamline workflows and tackle complex diagnostics with confidence.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.